Germany
Jorg Thomaier, who has been head of IP at the German pharma company since 2010, will leave later this year and hand the reins to the company’s head of patents
Leaders at the IP firms, which have joined forces with backing from a PE investor, share their vision of building the number one pan-European IP practice
Stefan Müller discusses managing deadlines, the importance of reflection, and why IP is more than just a 'nice to have'
Börge Seeger reveals the similarities between IP strategy and F1, and opines on bookshops, espresso machines, and late-night emails
Sponsored
Sponsored
-
Sponsored by Maiwald Intellectual PropertyMatthias Hoffmann of Maiwald discusses the uncertainty over the transfer of priority rights and the joint applicants approach at the EPO -
Sponsored by Maiwald Intellectual PropertyChristian Meyer of Maiwald discusses a case concerning the domain muenchen.de, in which a reference to a USB stick was found to be admissible in an application for an injunction
-
Sponsored by Maiwald Intellectual PropertyStefanie Parchmann of Maiwald considers the long-awaited referral to the Enlarged Board of Appeal regarding plausibility
-
Sponsored by Maiwald Intellectual PropertyDr Gisela Grabow of Maiwald explains the importance of a comprehensive approach to the revision of pharmaceutical legislation that considers the relationship with IP rights and the Action Plan on IP
-
Sponsored by Maiwald Intellectual PropertyChristian Meyer of Maiwald looks at the ineffective enforcement of a preliminary injunction in a German case concerning the requirements for a bank guarantee as security
-
Sponsored by Maiwald Intellectual PropertyAnnelie Wünsche and Stefanie Parchmann of Maiwald discuss double patenting before the EPO
